In this observational study researchers want to gather more information about bone fractures and survival in castration-resistant prostate cancer (CRPC) patients treated with radium-223 in routine clinical practice in Sweden. The goal is to estimate the proportion of new cases (incidence) of symptomatic bone fractures and to estimate the proportion of death occurred in years of observation time per person (person years). Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
Study Type
OBSERVATIONAL
Enrollment
1,434
Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.
Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
Database Study
Database Study, Sweden
Bone fractures requiring admission to a hospital or treated in an outpatient setting, as recorded or captured in the PCBaSe
PCBaSe: Prostate Cancer data Base Sweden
Time frame: Retrospectively analysis from November 2013 to December 2018
Death due to all causes
Time frame: Retrospectively analysis from November 2013 to December 2018
Death due to prostate cancer
Time frame: Retrospectively analysis from November 2013 to December 2018
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.